SI2263694T1 - Antitumorsko sredstvo, ki obsega inhibitor histon-deacetilaze FK228 in inhibitor topoizomeraze II doksorubicin - Google Patents

Antitumorsko sredstvo, ki obsega inhibitor histon-deacetilaze FK228 in inhibitor topoizomeraze II doksorubicin

Info

Publication number
SI2263694T1
SI2263694T1 SI200432064T SI200432064T SI2263694T1 SI 2263694 T1 SI2263694 T1 SI 2263694T1 SI 200432064 T SI200432064 T SI 200432064T SI 200432064 T SI200432064 T SI 200432064T SI 2263694 T1 SI2263694 T1 SI 2263694T1
Authority
SI
Slovenia
Prior art keywords
inhibitor
topoisomerase
histone deacetylase
doxorubicin
antitumor agent
Prior art date
Application number
SI200432064T
Other languages
English (en)
Slovenian (sl)
Inventor
Yoshinori Naoe
Yuka Sasakawa
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of SI2263694T1 publication Critical patent/SI2263694T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
SI200432064T 2003-09-25 2004-09-24 Antitumorsko sredstvo, ki obsega inhibitor histon-deacetilaze FK228 in inhibitor topoizomeraze II doksorubicin SI2263694T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003334340 2003-09-25
JP2003344315 2003-10-02
EP10163527.4A EP2263694B1 (en) 2003-09-25 2004-09-24 Antitumor agent comprising the histone deacetylase inhibitor FK228 and the topoisomerase II inhibitor doxorubicin

Publications (1)

Publication Number Publication Date
SI2263694T1 true SI2263694T1 (sl) 2013-09-30

Family

ID=34380371

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200432064T SI2263694T1 (sl) 2003-09-25 2004-09-24 Antitumorsko sredstvo, ki obsega inhibitor histon-deacetilaze FK228 in inhibitor topoizomeraze II doksorubicin

Country Status (14)

Country Link
US (1) US7314862B2 (US07314862-20080101-C00003.png)
EP (2) EP2263694B1 (US07314862-20080101-C00003.png)
JP (1) JP4779971B2 (US07314862-20080101-C00003.png)
AT (1) ATE471740T1 (US07314862-20080101-C00003.png)
CA (1) CA2540108A1 (US07314862-20080101-C00003.png)
CY (1) CY1114359T1 (US07314862-20080101-C00003.png)
DE (1) DE602004027824D1 (US07314862-20080101-C00003.png)
DK (1) DK2263694T3 (US07314862-20080101-C00003.png)
ES (2) ES2425083T3 (US07314862-20080101-C00003.png)
MX (1) MXPA06003222A (US07314862-20080101-C00003.png)
PL (2) PL1670514T3 (US07314862-20080101-C00003.png)
PT (1) PT2263694E (US07314862-20080101-C00003.png)
SI (1) SI2263694T1 (US07314862-20080101-C00003.png)
WO (1) WO2005030239A2 (US07314862-20080101-C00003.png)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2298414C2 (ru) * 2001-08-21 2007-05-10 Астеллас Фарма Инк. Медицинское применение ингибитора гистоновой дезацетилазы и способ оценки его противоопухолевого действия
EP1492596A1 (en) * 2002-04-05 2005-01-05 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide for therapy of kidney cancer
EP1595952A4 (en) * 2003-02-19 2008-05-21 Astellas Pharma Inc METHOD FOR EVALUATING THE ANTITUMOR EFFECT OF A HISTONE DEACETYLASE INHIBITOR
EP1608628A2 (en) * 2003-03-17 2005-12-28 Takeda San Diego, Inc. Histone deacetylase inhibitors
PT2263694E (pt) 2003-09-25 2013-08-27 Astellas Pharma Inc Agente antitumoral compreendendo o inibidor da histona desacetilase fk228 e o inibidor da topoisomerase ii, doxorrubicina
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
EP1824831A2 (en) * 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2008540574A (ja) * 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
ZA200800901B (en) * 2005-07-14 2010-05-26 Takeda San Diego Inc Histone deacetylase inhibitors
WO2007040522A1 (en) * 2005-09-30 2007-04-12 The Ohio State Research Foundation Antitumor agents
EP1965824A4 (en) * 2005-11-18 2011-10-19 Gloucester Pharmaceuticals Inc METABOLITENE DERIVATIVES OF HDAC INHIBITOR FK228
WO2007084390A2 (en) * 2006-01-13 2007-07-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2650520A1 (en) * 2006-04-24 2008-01-31 Gloucester Pharmaceuticals Treatment of ras-expressing tumors
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
JP2010514777A (ja) * 2006-12-26 2010-05-06 ファーマサイクリックス，インク． 併用療法においてヒストンデアセチラーゼ阻害剤を使用し、バイオマーカーをモニタする方法
CN107090482A (zh) 2006-12-29 2017-08-25 细胞基因公司 制备Romidepsin
BRPI0720734A2 (pt) * 2006-12-29 2014-01-07 Gloucester Pharmaceuticals Inc Preparação da romidepsina
WO2009002941A1 (en) * 2007-06-22 2008-12-31 Board Of Regents, The University Of Texas System Composition and method for the treatment of diseases affected by histone deacetylase inhibitors
US20110021517A1 (en) * 2008-02-26 2011-01-27 Nerviano Medical Sciences S.R.L. Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents
RU2016149485A (ru) * 2010-07-12 2018-10-31 Селджин Корпорейшн Твердые формы ромидепсина и их применение
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
CN103917231B (zh) 2011-09-13 2016-09-28 药品循环有限责任公司 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
WO2014069255A1 (ja) * 2012-11-01 2014-05-08 公益財団法人微生物化学研究会 抗がん剤、及び併用抗がん剤
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
CN116327887B (zh) * 2023-04-24 2023-11-03 南京捷因诊断技术有限公司 一种lsd1抑制剂作为抗肿瘤药物的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US486379A (en) * 1892-11-15 Hame-tug
US574455A (en) * 1897-01-05 Switch-lock
US3997633A (en) * 1975-06-24 1976-12-14 Max Leva Contact towers with leak-proof support of improved plate subassembly
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
US4348388A (en) * 1980-04-02 1982-09-07 G.D. Searle & Co. 11-Amino-11-deoxydaunorubicin and analogs
GB8426672D0 (en) * 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
US4950755A (en) * 1985-08-12 1990-08-21 Ohio State University Bis(morpholinomethyl) derivative of 1,2-bis(dioxopiperizinyl)propane
US5242901A (en) * 1988-01-27 1993-09-07 New York University Reduction of anthracycline induced cardiotoxicity
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
JPH05507480A (ja) * 1990-05-26 1993-10-28 ビイク　グルデン　ロンベルク　ヒエーミツシエ　フアブリーク　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツング 医薬品抵抗性の克服の際に使用するための１，４―ジヒドロピリジン
US5620961A (en) * 1994-04-25 1997-04-15 Markovic; Nenad S. Fructose ester-β-cyclodextrin complexes and processes for making and using same
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US6020373A (en) * 1995-10-20 2000-02-01 Eastern Virginia Medical School Chelate derivatives as protectors against tissue injury
US5780054A (en) * 1996-01-17 1998-07-14 University Of British Columbia Methods for increasing the circulation half-life of protein-based therapeutics
US6451784B1 (en) * 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
BR9713661A (pt) * 1996-12-30 2000-10-24 Battelle Memorial Institute Formulação e método para o tratamento de neoplasmas por inalação
US7229841B2 (en) * 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US6286513B1 (en) * 1998-10-22 2001-09-11 Jessie L. Au Methods for treating superficial bladder carcinoma
US6197809B1 (en) * 1998-12-23 2001-03-06 Ardenia Investments Ltd. Compounds for the treatment of cancer
US20030144570A1 (en) * 1999-11-12 2003-07-31 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
KR20100035666A (ko) * 1999-11-23 2010-04-05 메틸진 인크. 히스톤 디아세틸라제의 억제제
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
DK1438966T3 (da) 1999-12-08 2007-06-11 Cyclacel Pharmaceuticals Inc Anvendelse af depsipeptid og analoger deraf som immunsupressive forbindelser til behandling af en infektiös sygdom, en autoimmun sygdom, allergiske reaktioner eller hyperproliferativ hudsygdom
US20020028237A1 (en) * 2000-04-20 2002-03-07 Colbern Gail T. Method for reducing toxicity of a cytotoxic agent
ATE425177T1 (de) 2000-07-17 2009-03-15 Astellas Pharma Inc Reduziertes fk228 und seine verwendung
WO2002024179A2 (en) * 2000-09-22 2002-03-28 Bristol-Myers Squibb Company Method for reducing toxicity of combined chemotherapies
AU2001290636A1 (en) * 2000-09-22 2002-04-02 Bristol-Myers Squibb Company Method for reducing toxicity of combined chemotherapies
US20020156023A1 (en) * 2000-12-06 2002-10-24 Tularik Inc. Lometrexol combination therapy
WO2002059375A2 (en) * 2001-01-26 2002-08-01 University Of Chicago Determination of ugt2b7 gene polymorphisms for predicting ugt2b7 substrate toxicity and for optimising drug dosage
ATE450265T1 (de) * 2001-03-23 2009-12-15 Shire Canada Inc Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
RU2298414C2 (ru) * 2001-08-21 2007-05-10 Астеллас Фарма Инк. Медицинское применение ингибитора гистоновой дезацетилазы и способ оценки его противоопухолевого действия
EP1492596A1 (en) 2002-04-05 2005-01-05 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide for therapy of kidney cancer
IL165214A0 (en) * 2002-05-17 2005-12-18 Aventis Pharma Sa Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
US20040136905A1 (en) * 2002-10-15 2004-07-15 Kent Thomas B. Magnetically guided particles for radiative therapies
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
US20050222013A1 (en) 2003-01-16 2005-10-06 Georgetown University Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy
WO2004103358A2 (en) 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents
PE20050206A1 (es) 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
CA2529840A1 (en) 2003-06-27 2005-01-06 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
PT2263694E (pt) 2003-09-25 2013-08-27 Astellas Pharma Inc Agente antitumoral compreendendo o inibidor da histona desacetilase fk228 e o inibidor da topoisomerase ii, doxorrubicina
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent

Also Published As

Publication number Publication date
US20050070467A1 (en) 2005-03-31
CY1114359T1 (el) 2016-08-31
WO2005030239A3 (en) 2005-07-28
MXPA06003222A (es) 2006-05-22
EP2263694B1 (en) 2013-06-12
CA2540108A1 (en) 2005-04-07
ES2344899T3 (es) 2010-09-09
DE602004027824D1 (de) 2010-08-05
ES2425083T3 (es) 2013-10-11
WO2005030239A2 (en) 2005-04-07
EP1670514B1 (en) 2010-06-23
EP1670514A2 (en) 2006-06-21
PL2263694T3 (pl) 2013-11-29
EP2263694A1 (en) 2010-12-22
JP2007506647A (ja) 2007-03-22
US7314862B2 (en) 2008-01-01
PT2263694E (pt) 2013-08-27
ATE471740T1 (de) 2010-07-15
JP4779971B2 (ja) 2011-09-28
DK2263694T3 (da) 2013-08-26
PL1670514T3 (pl) 2010-11-30

Similar Documents

Publication Publication Date Title
SI2263694T1 (sl) Antitumorsko sredstvo, ki obsega inhibitor histon-deacetilaze FK228 in inhibitor topoizomeraze II doksorubicin
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
TW200738725A (en) Unsaturated mTOR inhibitors
HK1086488A1 (en) Compound and use thereof for the treatment of cancer
IL239913B (en) The use of delvavancin in a pharmaceutical carrier is accepted in the production of a drug for the treatment of bacterial infections
MY148491A (en) FUSED BICYCLIC mTOR INHIBITORS
EP1778294A4 (en) ANTIMICROBIAL PHOTODYNAMIC THERAPY COMPOUND BASED ON ERYTHROSINE AND USE THEREOF
MX2019010879A (es) Tratamiento de cancer.
HK1080447B (zh) 視黃醇衍生物、它們在治療癌症和增强其它細胞毒性劑功效中的應用
EP1961418A4 (en) USE OF ISOTHIOCYANATE-BASED COMPOUNDS IN THE TREATMENT OF PROSTATIC DISEASES AND SKIN CANCER
WO2003080582A3 (de) Fredericamycin-derivate
IL174121A0 (en) Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
WO2009156735A3 (en) New therapeutic agents
HK1072443A1 (en) Immunoconjugates for the treatment of tumours
MXPA03010761A (es) Combinaciones farmaceuticas.
UA87877C2 (en) Pegylated liposomal doxorubicin in combination with ecteinescidin 743
TW200508199A (en) Novel compound
EP2161037A3 (en) Camptothecin-Somatostatin conjugates
EP1364652A4 (en) CURE FOR LUNG CANCER
HK1079116A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
AU2003296545A1 (en) Use of a trpm8-activating substance for the treatment of tumours
ZA200209835B (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or anti-metabolites.
WO2003020371A3 (en) Potentiator composition comprising a terpene for enhancing a therapeutical effect of antitumoral agents in the treatment of cancer
AU2003296242A1 (en) Thia-epothilone derivatives for the treatment of cancer
AU2003288263A1 (en) Use of substituted acrylolyl distamycin derivatives in combination with demethylating agents, in the treatment of cancer